RxDoctor Payments Data

Brian Corbett, DO

Cardiovascular Disease · Camden, NJNPI 1649437690

Payments from drug & device makers

$15,831in general payments, 2019–2025

Across 872 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Medtronic$2K
  • Abbott$1K
  • Novartis$1K
  • Pfizer$722
  • Amgen$689
  • plus $8K from 42 others

What the payments were for

  • Travel & lodging$6894%
  • Food & beverage$15,14296%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,831 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$177,905
Medicare patients
627
Services billed
1,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$273,060
XareltoRivaroxaban114$171,134
Repatha SureclickEvolocumab99$141,266
EntrestoSacubitril/Valsartan86$113,698
FarxigaDapagliflozin Propanediol27$28,182
BrilintaTicagrelor13$15,786
Praluent PenAlirocumab15$14,970
NexlizetBempedoic Acid/Ezetimibe12$14,344
Rosuvastatin Calcium406$6,770
Metoprolol Succinate340$5,985
Atorvastatin Calcium426$5,751
Valsartan84$3,349
Ezetimibe120$3,056
Carvedilol237$2,516
Torsemide96$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$722$273,060208 claims
Johnson & JohnsonXarelto$2,065$171,134114 claims
NovartisEntresto$1,207$113,69886 claims
AstraZenecaFarxiga, Brilinta$469$43,96840 claims
Esperion Therapeutics, Inc.Nexlizet$207$14,34412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →